Transcatheter Mitral Valve Repair Market (2026-2036)

In terms of volume, the global Transcatheter Mitral Valve Repair Market was valued at 68.0 thousand procedures in 2025. This market is expected to reach 255.0 thousand procedures by 2036 from an estimated 78.0 thousand procedures in 2026, registering a CAGR of 12.6% during the forecast period (2026-2036).

The transcatheter mitral valve repair market covers edge-to-edge repair devices, indirect and direct annuloplasty systems, transcatheter chordal repair devices and the delivery systems and accessories supplied with them, across secondary and primary mitral regurgitation and the full range of surgical risk categories. The growth of this market is driven by randomised evidence against medical therapy and against surgery, by heart failure services referring patients who were not previously considered for intervention, by intracardiac imaging shortening the procedure, and by domestic devices entering the Chinese market.

Volume grows faster than value in this market, at 12.6% against 11.7%, so average selling price falls from USD 22,790 in 2025 to USD 22,560 in 2026 and USD 20,780 by 2036. The decline reflects domestically produced devices taking unit share in China at prices well below imported systems and tender pressure in the established Western markets, rather than price reductions on any individual product.

The RESHAPE-HF2 trial, presented at the same congress and published in the New England Journal of Medicine, enrolled 505 patients of 621 screened with symptomatic heart failure and grade 3 to 4 plus secondary mitral regurgitation despite maximally tolerated guideline-directed medical therapy, randomising 250 to transcatheter edge-to-edge repair with that therapy and 255 to the therapy alone, with first or recurrent heart failure hospitalisation or cardiovascular death at 24 months occurring at 37.0 events per 100 patient-years in the repair group against 58.9 in the control group, a rate ratio of 0.64 with a 95% confidence interval of 0.48 to 0.85 at p equal to 0.002 and a number needed to treat of 5.1. Heart failure hospitalisation alone fell from 46.6 to 26.9 events per 100 patient-years, mitral regurgitation was grade 2 plus or less at 12 months in 90.4% of the repair group against 36.1% of the control group, and all-cause mortality was 22.3% against 29.6% at p equal to 0.09, so the benefit arose predominantly from avoided hospitalisation rather than from survival. A benefit concentrated in avoided hospitalisation rather than survival is the more useful finding commercially, because a payer can verify hospitalisation avoided in its own claims data in a way it cannot verify a mortality benefit at distant follow-up.

Transcatheter mitral valve repair modifies the existing valve rather than replacing it, most commonly by clipping the two leaflets together at the point of regurgitation so that the valve closes in two orifices instead of one. Annuloplasty approaches reduce the circumference of the annulus to bring the leaflets closer, and chordal repair replaces or shortens the cords that tether the leaflets. The native valve stays in place in all of these, which is what distinguishes repair from replacement and what sets the limits of what it can treat.

The RESHAPE-HF2 trial, presented at the same congress and published in the New England Journal of Medicine, enrolled 505 patients of 621 screened with symptomatic heart failure and grade 3 to 4 plus secondary mitral regurgitation despite maximally tolerated guideline-directed medical therapy, randomising 250 to transcatheter edge-to-edge repair with that therapy and 255 to the therapy alone, with first or recurrent heart failure hospitalisation or cardiovascular death at 24 months occurring at 37.0 events per 100 patient-years in the repair group against 58.9 in the control group, a rate ratio of 0.64 with a 95% confidence interval of 0.48 to 0.85 at p equal to 0.002 and a number needed to treat of 5.1. Heart failure hospitalisation alone fell from 46.6 to 26.9 events per 100 patient-years, mitral regurgitation was grade 2 plus or less at 12 months in 90.4% of the repair group against 36.1% of the control group, and all-cause mortality was 22.3% against 29.6% at p equal to 0.09, so the benefit arose predominantly from avoided hospitalisation rather than from survival. A number needed to treat of 5.1 over 24 months is favourable for an elective cardiac intervention, and the concentration of benefit in hospitalisation rather than mortality gives a payer a cost offset it can measure directly rather than a survival claim it has to accept on trial follow-up.

The MATTERHORN trial, presented at the European Society of Cardiology Congress in 2024 and published simultaneously in the New England Journal of Medicine, randomised 210 patients at high surgical risk with secondary mitral regurgitation, a left ventricular ejection fraction of at least 20% and heart failure symptoms despite optimal medical therapy, across 16 centres in Germany, to transcatheter edge-to-edge repair or to mitral valve surgery in which 72% of the surgical arm underwent repair and 28% underwent replacement, with the one-year composite of death, heart failure hospitalisation, mitral reintervention, assist device implantation and stroke occurring in 16.7% of the transcatheter group and 22.5% of the surgical group, establishing non-inferiority at p below 0.01. Non-inferiority to surgery in a trial where most of the surgical arm received repair rather than replacement moves the comparator for this therapy from medical management to the operation, which is the comparison that determines whether a cardiac surgical programme refers a patient or operates.

Secondary mitral regurgitation arises because the ventricle has dilated and no longer holds the valve in a competent position, so the valve itself is structurally normal and the disease is a consequence of heart failure. Those patients sit in heart failure clinics on medical therapy rather than in surgical referral pathways, which is why volume in this indication depends on heart failure services identifying regurgitation and referring it rather than on any change in device availability.

Primary mitral regurgitation arises from the valve itself, through degeneration, prolapse or chordal rupture, and surgical repair in those patients has long-term results that transcatheter repair does not yet match. Transcatheter treatment therefore concentrates in primary regurgitation patients at high surgical risk, and a younger patient with degenerative disease and acceptable operative risk is still referred for an operation in most centres.

Abbott announced on 27 May 2025 that the FDA had approved the Tendyne transcatheter mitral valve replacement system for patients with mitral valve disease arising from severe mitral annular calcification who are at high risk for open-heart surgery and whose valve cannot be successfully repaired with the MitraClip device. The replacement indication is therefore defined by the limits of repair rather than competing within them, so the population repair cannot serve, principally severe annular calcification and anatomies in which leaflet capture is not feasible, moves to replacement rather than being lost to medical therapy. Repair volumes grow while the repair share of total mitral intervention falls.

Anatomical suitability limits how many patients a device can treat regardless of referral volume. Leaflet length, the size and location of the regurgitant orifice, the degree of annular calcification and the presence of a cleft or multiple jets each determine whether edge-to-edge repair can be performed and whether it will reduce regurgitation sufficiently. Screening by echocardiography and computed tomography therefore excludes a meaningful proportion of referrals before any procedure is planned.

Residual regurgitation after the procedure determines whether the clinical benefit is realised, and RESHAPE-HF2 reported grade 2 plus or less in 90.4% of the repair group at 12 months against 36.1% of the control group. Achieving that result depends on operator experience, on imaging quality during the procedure and on device selection for the anatomy, which is why outcomes vary between centres more than they vary between devices.

Intracardiac echocardiography is displacing transoesophageal guidance in some centres because it avoids general anaesthesia and the oesophageal intubation that comes with it, which shortens the procedure, allows conscious sedation and reduces the staffing required. That matters for throughput rather than for outcome, and throughput is the constraint in programmes where the referral volume now exceeds the capacity to treat.

Chinese manufacturers have brought domestically produced edge-to-edge devices to their own market at prices well below imported systems, and national reimbursement arrangements there have expanded access from a small base. Regional price differentials consequently affect reported market value more than they affect procedure numbers, which is why the value and volume growth rates in this market diverge. A reader comparing national markets on revenue alone will therefore understate Chinese activity relative to the number of patients treated, and the two measures have to be read together. The report therefore presents procedures and revenue by region separately rather than relying on either as the description of regional position.